Rapid whole monoclonal antibody analysis by mass spectrometry: An ultra scale-down study of the effect of harvesting by centrifugation on the post-translational modification profile

Biotechnology and Bioengineering

Volumn 107, Issue 1, 2010, Pages 85-95

  Reid, C Q ^a   Tait, A ^a   Baldascini, H ^a   Mohindra, A ^b   Racher, A ^b   Bilsborough, S ^c   Smales, C M ^d   Hoare, M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONZA AG   (Switzerland)

^c AGILENT TECHNOLOGIES   (United Kingdom)

^d UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Bioprocess validation; Glycosylation; Mammalian cell culture; Mass spectrometry; Monoclonal antibody; Ultra scale down

Indexed keywords

ANTIBODY MOLECULES; BIOPROCESSES; CONSISTENT QUALITY; DESIGN DECISIONS; DEVELOPMENT PROCESS; DRUG CANDIDATES; GLYCANS; HEAVY CHAIN; LYSINE RESIDUES; MAMMALIAN CELL CULTURE; OPERATING CONDITION; PLATFORM PROCESS; POST-TRANSLATIONAL MODIFICATIONS; PROCESS STREAMS; PRODUCTION PROCESS; RECOVERY STAGES; REPRODUCIBILITIES; SELECTION CRITERIA; ULTRA SCALE-DOWN;

AMINO ACIDS; ANIMAL CELL CULTURE; CENTRIFUGATION; ESTERIFICATION; GLYCOSYLATION; MAMMALS; MASS SPECTROMETRY; MOLECULAR STRUCTURE; MONOCLONAL ANTIBODIES; OLIGOMERS; PROCESS ENGINEERING; SURFACE PLASMON RESONANCE; TRANSLATION (LANGUAGES);

CELL CULTURE;

IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

ANIMAL CELL; ANTIBODY STRUCTURE; ARTICLE; BIOPROCESS; CARBOXY TERMINAL SEQUENCE; CENTRIFUGATION; CONTROLLED STUDY; MASS SPECTROMETRY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING;

ANIMALS; ANTIBODIES, MONOCLONAL; CENTRIFUGATION; CHO CELLS; CRICETINAE; CRICETULUS; MASS SPECTROMETRY; PEPTIDE MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS;

MAMMALIA;

EID: 77956237886     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22790     Document Type: Article

References (65)

1. Andersen DC, Goochee CF. 1994. The effect of cell-culture conditions on the oligosaccharide structures of secreted glycoproteins. Curr Opin Biotechnol 5(5):546-549.
2. Bailey MJ, Hooker AD, Adams CS, Zhang SH, James DC. 2005. A platform for high-throughput molecular characterization of recombinant monoclonal antibodies. J Chromatogr B 826(1-2):177-187.
3. Beck A, Bussat MC, Zorn N, Robillard V, Klinguer-Hamour C, Chenu S, Goetsch L, Corvaia N, Van Dorsselaer A, Haeuw JF. 2005. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NSO cells. J Chromatogr B 819(2):203-218. (Pubitemid 40521956)
4. Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. 1997. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci 6(2):407-415.
5. Bongers J, Cummings JJ, Ebert MB, Federici MM, Gledhill L, Gulati D, Hilliard GM, Jones BH, Lee KR, Mozdzanowski J, Naimoli M, Burman S. 2000. Validation of a peptide mapping method for a therapeutic monoclonal antibody: What could we possibly learn about a method we have run 100 times? J Pharmaceut Biomed 21(6):1099-1128.
6. Boychyn M, Yim SSS, Shamlou PA, Bulmer M, More J, Hoare A. 2001. Characterization of flow intensity in continuous centrifuges for the development of laboratory mimics. Chem Eng Sci 56(16):4759-4770.
7. Boychyn M, Yim SSS, Bulmer M, More J, Bracewell DG, Hoare M. 2004. Performance prediction of industrial centrifuges using scale-down models. Bioproc Biosyst Eng 26(6):385-391.
8. Boyiadzis M, Foon KA. 2008. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 8(8):1151-1158.
9. Cabrera G, Cremata JA, Valdes R, Garcia R, Gonzalez Y, Montesino R, Gomez H, Gonzalez M. 2005. Influence of culture conditions on the N-glycosylation of a monoclonal antibody specific for recombinant hepatitis B surface antigen. Biotechnol Appl Biochem 41(Pt 1):67-76.
10. Chames P, Van Regenmortel M, Weiss E, Baty D. 2009. Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol 157(2):220-233.
11. Chaplen FWR. 1998. Incidence and potential implications of the toxic metabolite methylglyoxal in cell culture: A review. Cytotechnology 26(3):173-183.
12. Damen CWN, Chen WB, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, Schellens JHM, Rosing H, Beijnen JH. 2009. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom 20(11):2021-2033.
13. Deng L, Wylie D, Tsao YS, Larkin B, Voloch M, Ling WLW. 2004. Detection and quantification of the human IgG4 half-molecule, HL, from unpurified cell-culture supernatants. Biotechnol Appl Biochem 40:261-269.
14. Dick LW, Kim C, Qiu DF, Cheng KC. 2007. Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides. Biotechnol Bioeng 97(3):544-553. (Pubitemid 46848069)
15. Dick LW, Qiu DF, Mahon D, Adamo M, Cheng KC. 2008. C-terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes. Biotechnol Bioeng 100(6):1132-1143.
16. Feige MJ, Groscurth S, Marcinowski M, Shimizu Y, Kessler H, Hendershot LM, Buchner J. 2009. An unfolded C(H)1 domain controls the assembly and secretion of IgG antibodies. Mol Cell 34(5):569-579.
17. Fernandez LEM, Kalume DE, Calvo L, Mallo MF, Vallin A, Roepstorff P. 2001. Characterization of a recombinant monoclonal antibody by mass spectrometry combined with liquid chromatography. J Chromatogr B 752(2):247-261.
18. Goochee CF, Gramer MJ, Andersen DC, Bahr JB, Rasmussen JR. 1991. The oligosaccharides of glycoproteins-Bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties. Biotechnology 9(12):1347-1355.
19. Harris RJ. 1995. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A 705(1):129-134.
20. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. 2001. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B 752(2):233-245.
21. Hooker AD, Goldman MH, Markham NH, James DC, Ison AP, Bull AT, Strange PG, Salmon I, Baines AJ, Jenkins N. 1995. N-glycans of recombinant human interferon-gamma change during batch culture of Chinese-Hamster ovary cells. Biotechnol Bioeng 48(6):639-648.
22. Hossler P, Khattak SF, Li ZJ. 2009. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19(9):936-949.
23. Huhn C, Selman MHJ, Ruhaak LR, Deelder AM, Wuhrer M. 2009. IgG glycosylation analysis. Proteomics 9(4):882-913.
24. Hutchinson N, Bingham N, Murrell N, Farid S, Hoare M. 2006. Shear stress analysis of mammalian cell suspensions for prediction of industrial centrifugation and its verification. Biotechnol Bioeng 95(3):483-491. (Pubitemid 44495383)
25. Jefferis R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol Progr 21(1):11-16.
26. Jefferis R. 2009. Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30(7):356-362.
27. Jenkins N, Parekh RB, James DC. 1996. Getting the glycosylation right: Implications for the biotechnology industry. Nat Biotechnol 14(8):975-981.
28. Jia XM, Olson DJH, Ross ARS, Wu LY. 2006. Structural and functional changes in human insulin induced by methylglyoxal. FASEB 20(9):1555-1557.
29. Kamoda S, Nomura C, Kinoshita M, Nishiura S, Ishikawa R, Kakehi K, Kawasaki N, Hayakawa T. 2004. Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis. J Chromatogr A 1050(2):211-216.
30. Kao YH, Schmidt MT, Laird MW, Wong RL, Hewitt DP. 2009. Prevention of disulfide bond reduction during recombinant production of polypeptides. US Patent: WO/2009/009523.
31. Kawasaki N, Itoh S, Hashii N, Takakura D, Qin Y, Huang XY, Yamaguchi T. 2009. The significance of glycosylation analysis in development of biopharmaceuticals. Biol Pharm Bull 32(5):796-800.
32. Korecka L, Bilkova Z, Holcapek M, Kralovsky J, Benes M, Lenfeld J, Minc N, Cecal R, Viovy JL, Przybylski M. 2004. Utilization of newly developed immobilized enzyme reactors for preparation and study of immunoglobulin G fragments. J Chromatogr B 808(1):15-24.
33. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. 2003. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325(5):979-989. (Pubitemid 36263407)
34. Kunkel JP, Jan DC, Butler M, Jamieson JC. 2000. Comparisons of the glycosylation of a monoclonal antibody produced under nominally identical cell culture conditions in two different bioreactors. Biotechnol Prog 16(3):462-470.
35. Lewis DA, Guzzetta AW, Hancock WS, Costello M. 1994. Characterization of humanized anti-Tac, an antibody-directed against the interleukin-2 receptor, using electrospray-ionization mass-spectrometry by direct infusion, Lc/Ms, and Ms/Ms. Anal Chem 66(5):585-595.
36. Liu HC, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. 2008. Heterogeneity of monoclonal antibodies. J Pharm Sci 97(7):2426-2447.
37. Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R. 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 157(11):4963-4969.
38. Lyubarskaya Y, Houde D, Woodard J, Murphy D, Mhatre R. 2006. Analysis of recombinant monoclonal antibody isoforms by electrospray ionization mass spectrometry as a strategy for streamlining characterization of recombinant monoclonal antibody charge heterogeneity. Anal Biochem 348(1):24-39. (Pubitemid 41796453)
39. Magnusson CGM, Bjornstedt M, Holmgren A. 1997. Human IgG is substrate for the thioredoxin system: Differential cleavage pattern of interchain disulfide bridges in IgG subclasses. Mol Immunol 34(10):709-717.
40. Majid FAA, Butler M, Al-Rubeai M. 2007. Glycosylation of an immunoglobulin produced from a murine hybridoma cell line: The effect of culture mode and the anti-apoptotic gene, bcl-2. Biotechnol Bioeng 97(1):156-169.
41. Mechref Y, Muzikar J, Novotny MV. 2005. Comprehensive assessment of N-glycans derived from a murine monoclonal antibody: A case for multimethodological approach. Electrophoresis 26(10):2034-2046. (Pubitemid 40796669)
42. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. 2000. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 37(12-13):697-706.
43. Mohan SB, Chohan SR, Eade J, Lyddiatt A. 1993. Molecular integrity of monoclonal-antibodies produced by hybridoma cells in batch culture and in continuous-flow culture with integrated product recovery. Biotechnol Bioeng 42(8):974-986.
44. Moorhouse KG, Nashabeh W, Deveney J, Bjork NS, Mulkerrin MG, Ryskamp T. 1997. Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDEC-C2B8 after papain digestion. J Pharm Biomed Anal 16(4):593-603. (Pubitemid 28044191)
45. Olivova P, Chen WB, Chakraborty AB, Gebler JC. 2008. Determination of N-glycosylation sites and site heterogeneity in a monoclonal antibody by electrospray quadrupole ion-mobility time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 22(1):29-40.
46. Paoli T, Faulkner J, O'Kennedy R, Keshavarz-Moore E. In press. A study of D-lactate and extracellular methylglyoxal production in lactate reutilising CHO cultures. Biotechnol Bioeng published online DOI 10.1002/bit.22757
47. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou QW. 2007. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 364(1):8-18.
48. Reichert JM. 2002. Therapeutic monoclonal antibodies: Trends in development and approval in the US. Curr Opin Mol Ther 4(2):110-118. (Pubitemid 34649801)
49. Robinson DK, Chan CP, Ip CY, Tsai PK, Tung J, Seamans TC, Lenny AB, Lee DK, Irwin J, Silberklang M. 1994. Characterization of a recombinant antibody produced in the course of a high-yield fed-batch process. Biotechnol Bioeng 44(6):727-735. (Pubitemid 24277100)
50. Rousseaux J, Rousseauxprevost R, Bazin H. 1989. Isolation and characterization of a Vh domain fragment from monoclonal rat Igg of Igg1 and Igg2a subclasses. Mol Immunol 26(1):27-32.
51. Roy BM, Rau TD, Balcarcel RR. 2004. Toxic concentrations of exogenously supplied methylglyoxal in hybridoma cell culture. Cytotechnology 46(2-3):97-107.
52. Santora LC, Krull IS, Grant K. 1999. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal Biochem 275(1):98-108.
53. Schahs M, Strasser R, Stadlmann J, Kunert R, Rademacher T, Steinkellner H. 2007. Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol J 5(5):657-663. (Pubitemid 47196370)
54. Schmidt MT, Sargis S, Chiu J, Sze-Khoo S, Mun M, Kao YH, Laird MW. 2010. Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing. Biotechnol Bioeng 106(3):452-461.
55. Schweikart F, Jones R, Jaton JC, Hughes GJ. 1999. Rapid structural characterisation of a murine monoclonal IgA alpha chain: heterogeneity in the oligosaccharide structures at a specific site in samples produced in different bioreactor systems. J Biotechnol 69(2-3):191-201.
56. Serrato JA, Hernandez V, Estrada-Mondaca S, Palomares LA, Ramirez OT. 2007. Differences in the glycosylation profile of a monoclonal antibody produced by hybridomas cultured in serum-supplemented, serum-free or chemically defined media. Biotechnol Appl Biochem 47(Pt 2):113-124.
57. Stern M, Herrmann R. 2005. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol Hemat 54(1):11-29. (Pubitemid 40387003)
58. Stigter ECA, de Jong GJ, van Bennekorn WP. 2007. Development of an open-tubular trypsin reactor for on-line digestion of proteins. Anal Bioanal Chem 389(6):1967-1977.
59. Tait AS, Aucamp JP, Bugeon A, Hoare M. 2009. Ultra scale-down prediction using microwell technology of the industrial scale clarification characteristics by centrifugation of mammalian cell broths. Biotechnol Bioeng 104(2):321-331.
60. Titchener-Hooker NJ, Dunnill P, Hoare M. 2008. Micro biochemical engineering to accelerate the design of industrial-scale downstream processes for biopharmaceutical proteins. Biotechnol Bioeng 100(3):473-487.
61. Waldmann TA, Morris JC. 2006. Development of antibodies and chimeric molecules for cancer immunotherapy. Adv Immunol 90:83-131.
62. Wang LT, Amphlett G, Lambert JM, Blattler W, Zhang W. 2005. Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry. Pharm Res 22(8):1338-1349. (Pubitemid 41176038)
63. Yan BX, Yates Z, Balland A, Kleemann GR. 2009. Human IgG1 hinge fragmentation as the result of H2O2-mediated radical cleavage. J Biol Chem 284(51):35390-35402.
64. Yu YQ, Gilar M, Kaska J, Gebler JC. 2005. A rapid sample preparation method for mass spectrometric characterization of N-linked glycans. Rapid Commun Mass Spectrom 19(16):2331-2336. (Pubitemid 41159741)
65. Zhang W, Marzilli LA, Rouse JC, Czupryn MJ. 2002. Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody. Anal Biochem 311(1):1-9. (Pubitemid 35463482)